Cha Bio&Diostech files IND for Pluristem’s PLX Cells with KFDA
This announcement comes, following a strategic alliance inked on 26 June 2013 between Cha and Pluristem Therapeutics, which is a developer of placenta-based cell therapies. As per the
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.